HAYWARD, Calif., May 3, 2012 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), today announced financial results and business highlights for the quarter ended March 31, 2012.
Total operating expenses for the first quarter ended March 31, 2012 were $20.1 million, as compared to $28.4 million for the fourth quarter ended December 31, 2011. The decrease in operating expenses can be primarily attributed to the completion of enrollment of the PEARL-SC study in the fourth quarter. The Company expects operating expenses to decline further in subsequent quarters following the discontinuation of varespladib development.
Anthera ended the first quarter of 2012 with approximately $44.0 million in cash and cash equivalents and short-term investments. This is compared to $67.4 million in cash and cash equivalents and short-term investments for the fourth quarter ended December 31, 2011. The Company expects cash burn for the second quarter ended June 30, 2012 to be approximately $13.0-15.0 million.
Anthera will host a conference call at 8:30 a.m. Eastern Time tomorrow, May 4, 2012. U.S. and Canadian participants may dial (877) 312-8807; international participants may dial (253) 237-1190. The Conference ID is 76225935. To access the 24-hour audio replay, U.S. and Canadian participants may dial (855) 859-2056; international participants may dial (404) 537-3406. The conference ID for the replay is 76225935. The audio replay will be available until May 11, 2012.
Recent Business Highlights and Upcoming Events:
*SELENA/SLEDAI -- Safety of Estrogen in Lupus Erythematosus National Assessment / Systemic Lupus Erythematosus Activity Index is a cumulative, weighted index of systemic lupus erythematosus disease activity.
About Anthera PharmaceuticalsAnthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases.
Safe Harbor Statement
Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," "project," or similar statements, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on Anthera's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially as set forth in Anthera's public filings with the SEC, including Anthera's Annual Report on Form 10-K for the year ended December 31, 2011. Anthera disclaims any intent or obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.
CONTACT: Bianca Nery of Anthera Pharmaceuticals, Inc., firstname.lastname@example.org or 510.856.5586.ANTHERA PHARMACEUTICALS, INC.A Development Stage CompanySTATEMENTS OF OPERATIONS(unaudited)(in thousands except share and per share data)Three Months Ended March 31,20122011OPERATING EXPENSE: Research and development
,317 General and administrative
2,3222,340Total operating expense
20,06018,657LOSS FROM OPERATIONS:
(20,060)(18,657)OTHER (EXPENSE)/INCOME:Other (expense)/income
(10)160Interest expense(843)(69)Total other (expense)/income
$ (20,913)$ (18,566)Net loss per share--basic and diluted
(0.56) Weighted-average number of shares used in per share calculation-- basic and diluted
41,000,42132,895,152ANTHERA PHARMACEUTICALS, INC.A Development Stage CompanyBALANCE SHEET DATA(unaudited)(in thousands except share amounts)March 31,2012December 31,2011Cash and cash equivalents
5,624Short term investments
9,493Total current liabilities, excluding current portion of notes payable
26,078Total notes payable
24,331Deficit accumulated during development stage
$ (221,892)$ (200,979)Total shareholders' (deficit) equity
9,084Common shares outstanding
|SOURCE Anthera Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved